A carregar...

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer

Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer (Auckl)
Main Authors: Tran, Phu N, Klempner, Samuel J
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5310702/
https://ncbi.nlm.nih.gov/pubmed/28210165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S94337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!